Journal List > J Korean Soc Menopause > v.17(3) > 1052064

Park, Kim, Lee, Lee, and Chung: Prevalence of Human Papilloma Virus Infection in Perimenopausal Women in Bucheon Province

Abstract

Objectives

To investigate the prevalence of human papillomavirus (HPV) infection in Bucheon province.

Methods

Two hundred eighty Korean women (average age 41.9, range 21~90 years) were enrolled, who received a regular thinprep pap test and an HPV deoxyribonucleic acid (DNA) chip test simultaneously at Soonchunhyang University Hospital, Bucheon, from February 2011 to March 2011.

Results

The overall prevalence of HPV infection was 33.9% (95/280). The prevalence of HPV infection in postmenopausal women (24.3%) was significantly lower than that of premenopausal women (37.1%, P = 0.049).

Conclusion

Although the prevalence of HPV infection in postmenopausal women was lower than that of premenopausal women, HPV infection is more critical in postmenopausal women as HPV infection in postmenopausal women is more likely to induce cervical cancer than in premenopausal women.

Figures and Tables

Table 1
Univariate comparison between the human papillomavirus (-) group and human papillomavirus (+) group
jksm-17-155-i001

Statistics were analyzed by t-test and chi-square test. HPV: human papillomavirus

Table 2
Human papillomavirus test & gynecological disease cross tabulation
jksm-17-155-i002

CIN: cervical intraepithelial neoplasia, HPV: human papillomavirus

Table 3
The rate of human papillomavirus infection by menopause status
jksm-17-155-i003

HPV: human papillomavirus. *P = 0.049, χ2-test.

Table 4
The distribution of HPV infection by risk group
jksm-17-155-i004

References

1. World Health Organization. Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals. 2007. cited by 2011 Aug 1. Geneva: World Health Organization;Available from: http://whqlibdoc.who.int/hq/2007/WHO_IVB_07.05_eng.pdf.
2. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007. 297:813–819.
3. Pham TH, Nguyen TH, Herrero R, Vaccarella S, Smith JS, Nguyen Thuy TT, et al. Human papillomavirus infection among women in South and North Vietnam. Int J Cancer. 2003. 104:213–220.
4. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995. 87:796–802.
5. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006. 24:Suppl 1. S16–S22.
6. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004. 324:17–27.
7. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006. 24:Suppl 3. S3S26–S34.
8. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002. 55:244–265.
9. Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev. 2001. 10:45–52.
10. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001. 183:8–15.
11. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, et al. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess. 1999. 3:i–iv. 1–196.
12. Park HB, Suh YH, Park CH. Clinical efficacy of cervicography in patients with atypical squamous cells of undetermined significance (ASCUS) on cervical cytology. Korean J Obstet Gynecol. 2003. 46:362–377.
13. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer. 2003. 103:413–421.
14. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000. 92:464–474.
15. Joo WD, Kim SH, Kim DY, Suh DS, Kim JH, Kim YM, et al. Prevalence of human papillomavirus infection in Korean women : risks of abnormal pap smear and cervical neoplasia. Korean J Gynecol Oncol Colposc. 2004. 15:309–316.
16. Bae JH, Lee SJ, Kim CJ, Hur SY, Park YG, Lee WC, et al. Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis. J Microbiol Biotechnol. 2008. 18:788–794.
17. Bratti MC, Rodriguez AC, Schiffman M, Hildesheim A, Morales J, Alfaro M, et al. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10,000 women in Guanacaste, Costa Rica. Rev Panam Salud Publica. 2004. 15:75–89.
18. Grinsztejn B, Veloso VG, Levi JE, Velasque L, Luz PM, Friedman RK, et al. Factors associated with increased prevalence of human papillomavirus infection in a cohort of HIV-infected Brazilian women. Int J Infect Dis. 2009. 13:72–80.
19. Kim YT. Natural history of HPV and carcinogenesis of cervical cancer. Korean J Obstet Gynecol. 2007. 50:711–720.
TOOLS
Similar articles